Quality indicators for multiple sclerosis

Abstract

Determining whether persons with multiple sclerosis (MS) receive appropriate, comprehensive healthcare requires tools for measuring quality. The objective of this study was to develop quality indicators for the care of persons with MS. We used a modified version of the RAND/UCLA Appropriateness Method in a two-stage process to identify relevant MS care domains and to assess the validity of indicators within high-ranking care domains. Based on a literature review, interviews with persons with MS, and discussions with MS providers, 25 MS symptom domains and 14 general health domains of MS care were identified. A multidisciplinary panel of 15 stakeholders of MS care, including 4 persons with MS, rated these 39 domains in a two-round modified Delphi process. The research team performed an expanded literature review for 26 highly ranked domains to draft 86 MS care indicators. Through another two-round modified Delphi process, a second panel of 18 stakeholders rated these indicators using a nine-point response scale. Indicators with a median rating in the highest tertile were considered valid. Among the most highly rated MS care domains were appropriateness and timeliness of the diagnostic work-up, bladder dysfunction, cognition dysfunction, depression, disease-modifying agent usage, fatigue, integration of care, and spasticity. Of the 86 preliminary indicators, 76 were rated highly enough to meet predetermined thresholds for validity. Following a widely accepted methodology, we developed a comprehensive set of quality indicators for MS care that can be used to assess quality of care and guide the design of interventions to improve care among persons with MS.

Keywords

health services research multiple sclerosis outcome research quality indicators

References

Holland NJ Overview of multiple sclerosis. Clinical Bulletin from the Professional Resource Center of the NMSS 2006: 1-7.

Wenger NS , Solomon DH , Roth CP , MacLean CH , Saliba D. , Kamberg CJ , et al. The quality of medical care provided to vulnerable community-dwelling older patients. Ann Intern Med 2003; 139: 740-747.

McGlynn EA , Asch SM , Adams J. , Keesey J. , Hicks J. , DeCristofaro A. , et al. The quality of health care delivered to adults in the United States. N Engl J Med 2003; 348: 2635-2645.

Cheng E. , Myers L. , Wolf S. , Shatin D. , Cui XP , Ellison G. , et al. Mobility impairments and use of preventive services in women with multiple sclerosis: Observational study. Br Med J 2001; 323: 968-969.

Vickrey BG , Edmonds ZV , Shatin D. , Shapiro MF , Delrahim S. , Belin TR , et al. General neurologist and subspecialist care for multiple sclerosis: Patients’ perceptions. Neurology 1999 ; 53: 1190-1197.

Vickrey BG , Shatin D. , Wolf SM , Myers LW , Belin TR , Hanson RA , et al. Management of multiple sclerosis across managed care and fee-for-service systems. Neurology 2000; 55: 1341-1349.

Donabedian A. Evaluating the quality of medical care. Milbank Mem Fund Q 1966; 44(Suppl): 166-206.

Centers for Medicare and Medicaid Services. Quality initiatives-general information. Available at: http://www.cms.hhs.gov/QualityInitiativesGenInfo/ (accessed 19 October 2009)

The Joint Commission. Stroke (stk) core measure set. Available at: http://www.jointcommission.org/PerformanceMeasurement/PerformanceMeasurement/STK+Core+Measures.htm (accessed 19 October 2009).

10.

Cheng EM and Fung CH Quality indicators for the care of stroke and atrial fibrillation in vulnerable elders. J Am Geriatr Soc 2007; 55(Suppl 2): S431-S437.

11.

Holloway RG , Vickrey BG , Benesch C. , Hinchey JA and Bieber J. Development of performance measures for acute ischemic stroke. Stroke 2001; 32: 2058-2074.

12.

Cheng EM , Siderowf A. , Swarztrauber K. , Eisa M. , Lee M. , Vassar S. , et al. Development of quality of care indicators for Parkinson’s disease. Mov Disord 2004; 19: 136-150.

13.

Feil DG , MacLean C. and Sultzer D. Quality indicators for the care of dementia in vulnerable elders. J Am Geriatr Soc 2007; 55(Suppl 2): S293-S301.

14.

Pugh MJ , Berlowitz DR , Montouris G. , Bokhour B. , Cramer JA , Bohm V. , et al. What constitutes high quality of care for adults with epilepsy? Neurology 2007; 69: 2020-2027.

15.

Compston A. , Confavreux C. , McDonald I. , Miller D. , Noseworthy JH , Smith K. , et al. McAlpine’s Multiple Sclerosis, 4th edn. Philadelphia, PA: Churchill Livingston Elsevier, 2006.

16.

Goodin DS , Frohman EM , Garmany Jr GP , Halper J. , Likosky WH , Lublin FD , et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002; 58: 169-178.

17.

National Institute for Health and Clinical Excellence. Multiple sclerosis: management of multiple sclerosis in primary and secondary care. Clinical Guidelines 8: 2003.

18.

Shekelle P. The appropriateness method. Med Decis Making 2004; 24: 228-231.

19.

Fitch K. , Bernstein S. , Aguilar M. , Burnand B. , LaCalle J. , Lazaro P. , et al. The RAND/UCLA appropriateness method user’s manual. RAND Monograph/Reports, 2001.

20.

Campbell SM , Braspenning J. , Hutchinson A. and Marshall MN Research methods used in developing and applying quality indicators in primary care. BMJ 2003 ; 326: 816-819.

21.

Agency for Healthcare Research and Quality. National guideline clearinghouse. Available at: http://www.guideline.gov/ (accessed 19 October 2009).

22.

The Cochrane Collaboration. Cochrane reviews . Available at: http://www.cochrane.org/reviews/ (accessed 19 October 2009).

23.

Agency for Healthcare Research and Quality. United States Preventive Services Task Force. Available at: http://www.ahrq.gov/clinic/uspstfix.htm (accessed 19 October 2009).

24.

American Academy of Neurology. Practice guidelines . Available at: http://www.aan.com/go/practice/guidelines (accessed 19 October 2009).

25.

National Multiple Sclerosis Society. Publications for healthcare professionals. Available at: http://www.nationalmssociety.org/for-professionals/healthcareprofessionals/publications/index.aspx (accessed 19 October 2009).

26.

World Health Organization. The international classification of functioning, disability and health. Towards a Common Language for Functioning, Disability and Health ICF , 2002: 1-21.

27.

Wenger NS and Shekelle PG Assessing care of vulnerable elders: Acove project overview. Ann Intern Med 2001; 135: 642-646.

28.

Goodin DS Survey of multiple sclerosis in Northern California. Northern California MS Study Group. Mult Scler 1999; 5: 78-88.

29.

Goodkin DE , Reingold S. , Sibley W. , Wolinsky J. , McFarland H. , Cookfair D. , et al. Guidelines for clinical trials of new therapeutic agents in multiple sclerosis: Reporting extended results from phase III clinical trials. National Multiple Sclerosis Society Advisory Committee on clinical trials of new agents in multiple sclerosis. Ann Neurol 1999; 46: 132-134.

30.

National Clinical Advisory Board of the National Multiple Sclerosis Society. Disease management consensus statement. Expert Opinion Paper from the National Clinical Advisory Board of the NMSS, 2007: 1-8.

31.

Miller CM The lived experience of relapsing multiple sclerosis: A phenomenological study . J Neurosci Nurs 1997; 29: 294-304.

32.

Johnson J. On receiving the diagnosis of multiple sclerosis: managing the transition . Mult Scler 2003; 9: 82.

33.

Edwards RG , Barlow JH and Turner AP Experiences of diagnosis and treatment among people with multiple sclerosis . J Eval Clin Practice 2008.

34.

Sorensen PS , Deisenhammer F. , Duda P. , Hohlfeld R. , Myhr KM , Palace J. , et al. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: Report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 2005; 12: 817-827.

35.

Goodin DS , Frohman EM , Hurwitz B. , O’Connor PW , Oger JJ , Reder AT , et al. Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact. An evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology . Neurology 2007; 68: 977-984.

36.

Higashi T. , Shekelle PG , Adams JL , Kamberg CJ , Roth CP , Solomon DH , et al. Quality of care is associated with survival in vulnerable older patients. Ann Intern Med 2005; 143: 274-281.

37.

Kahn KL , Malin JL , Adams J. and Ganz PA

Developing a reliable, valid, and feasible plan for quality-of-care measurement for cancer: how should we measure?

Med Care 2002; 40: I1173-I1185.

38.

MacLean CH , Louie R. , Shekelle PG , Roth CP , Saliba D. , Higashi T. , et al. Comparison of administrative data and medical records to measure the quality of medical care provided to vulnerable older patients. Medical Care 2006; 44: 141-148.

39.

Steel N. , Melzer D. , Shekelle PG , Wenger NS , Forsyth D. and McWilliams BC Developing quality indicators for older adults: transfer from the USA to the UK is feasible. Qual Saf Health Care 2004; 13: 260-264.

40.

Marshall MN , Shekelle PG , McGlynn EA , Campbell S. , Brook RH and Roland MO

Can health care quality indicators be transferred between countries?

Qual Saf Health Care 2003 ; 12: 8-12.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.01 MB

0.06 MB

0.03 MB